Search

Richard Eric Chipkin

from Bethesda, MD
Age ~74

Richard Chipkin Phones & Addresses

  • 5816 Cheshire Dr, Bethesda, MD 20814 (301) 897-8809 (301) 897-8864 (301) 919-2020
  • Rehoboth Beach, DE
  • Wethersfield, CT
  • 53 Francisco Ave, Caldwell, NJ 07006 (973) 226-4312
  • West Caldwell, NJ
  • 50 Lindsley Rd, Cedar Grove, NJ 07009 (973) 785-0471
  • Bloomfield, NJ

Resumes

Resumes

Richard Chipkin Photo 1

Richard Chipkin

View page
Location:
Washington D.C. Metro Area
Industry:
Biotechnology

Business Records

Name / Title
Company / Classification
Phones & Addresses
Richard Chipkin
Chief Executive Officer
Psychiatric Genomics, Inc
Bio-Technical Research
8401 Conn Ave, Bethesda, MD 20815
(240) 683-9540

Publications

Us Patents

Methods Of Treating Pain And Inflammation With 4,7-Dimethyl-2-(4-Pyridinyl)-1,2,4,-Triazolo[1,5-A]Pyrimidin-5(4H)-One Or The Pharmaceutically Acceptable Salts Or Solvates Thereof

View page
US Patent:
46147438, Sep 30, 1986
Filed:
Dec 27, 1983
Appl. No.:
6/566093
Inventors:
Richard E. Chipkin - Bloomfield NJ
Joseph T. Witkowski - Morris Township, Morris County NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 31505
C07D48704
US Classification:
514258
Abstract:
The compound 4,7-dimethyl-2-(4-pyridinyl)-1,2,4-triazolo[1,5-a]pyrimidin-5(4H)-one and the pharmaceutically acceptable salts thereof are analgesic and anti-inflammatory agents. Methods for preparing and using the compound and salts are described.

Assay Kit And Methods For Neuroleptic Drugs

View page
US Patent:
51048140, Apr 14, 1992
Filed:
Dec 21, 1990
Appl. No.:
7/631220
Inventors:
Richard Chipkin - West Caldwell NJ
Robert D. McQuade - Scotch Plains NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
G01N 33567
C07D22316
US Classification:
436504
Abstract:
The invention describes a kit and a method useful for analyzing the plasma concentration of an active neuroleptic drug known to have D-1 receptor antagonist properties utilizing labeled [-]trans 6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naphtho-[2 ,1-b]-azepine.

Fused Benzazepines For Treatment Of Stuttering

View page
US Patent:
20160271141, Sep 22, 2016
Filed:
Oct 17, 2014
Appl. No.:
15/030271
Inventors:
- Germantown MD, US
Richard E. CHIPKIN - Bethesda MD, US
International Classification:
A61K 31/55
A61K 45/06
A61K 9/00
Abstract:
The present invention encompasses methods of treating a subject who stutters. The methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.
Richard Eric Chipkin from Bethesda, MD, age ~74 Get Report